{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:02Z","timestamp":1794047462733,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2023.283846","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T03:06:51Z","timestamp":1709176011000},"page":"2277-2283","source":"Crossref","is-referenced-by-count":6,"title":["Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: &lt;i&gt;post-hoc&lt;\/i&gt; analysis of a large clinical trial safety database"],"prefix":"10.3324","volume":"109","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Salmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"63640","doi-asserted-by":"crossref","unstructured":"Tam CS, Dimopoulos M, Garcia-Sanz R. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022; 6(4):1296-1308.","DOI":"10.1182\/bloodadvances.2021005621"},{"key":"63641","doi-asserted-by":"crossref","unstructured":"Hillmen P, Eichhorst B, Brown JR. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial. J Clin Oncol. 2023; 41(5):1035-1045.","DOI":"10.1200\/JCO.22.00510"},{"key":"63642","doi-asserted-by":"crossref","unstructured":"Brown JR, Eichhorst B, Hillmen P. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023; 388(4):319-332.","DOI":"10.1056\/NEJMoa2211582"},{"key":"63643","doi-asserted-by":"crossref","unstructured":"Tam CS, Garcia-Sanz R, Opat S. ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenstr\u00f6m macroglobulinemia. J Clin Oncol. 2022; 40(s16):7521.","DOI":"10.1200\/JCO.2022.40.16_suppl.7521"},{"key":"63644","doi-asserted-by":"crossref","unstructured":"Tam CS, Opat S, D\u2019Sa S. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020; 136(18):2038-2050.","DOI":"10.1182\/blood.2020006844"},{"key":"63645","doi-asserted-by":"crossref","unstructured":"Honda F, Kano H, Kanegane H. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol. 2012; 13(4):369-378.","DOI":"10.1038\/ni.2234"},{"key":"63646","doi-asserted-by":"crossref","unstructured":"Estupi\u00f1\u00e1n HY, Berglof A, Zain R. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol. 2021; 9:630942.","DOI":"10.3389\/fcell.2021.630942"},{"key":"63647","doi-asserted-by":"crossref","unstructured":"Thandra KC, Barsouk A, Saginala K. Epidemiology of non-Hodgkin\u2019s lymphoma. Med Sci (Basel). 2021; 9(1):5.","DOI":"10.3390\/medsci9010005"},{"key":"63648","doi-asserted-by":"crossref","unstructured":"Hester LL, Park SI, Wood WA. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes. Cancer. 2019; 125(7):1101-1112.","DOI":"10.1002\/cncr.31821"},{"key":"63649","doi-asserted-by":"crossref","unstructured":"Coutre SE, Byrd JC, Hillmen P. Long-term safety of singleagent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019; 3(12):1799-1807.","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"63650","doi-asserted-by":"crossref","unstructured":"Gordon MJ, Jones JE, George B. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: focus on hypertension and cardiovascular toxicity. Cancer. 2023; 129(14):2192-2200.","DOI":"10.1002\/cncr.34787"},{"key":"63651","doi-asserted-by":"crossref","unstructured":"Brown JR, Moslehi J, O\u2019Brien S. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica. 2017; 102(10):1796-1805.","DOI":"10.3324\/haematol.2017.171041"},{"key":"63652","doi-asserted-by":"crossref","unstructured":"Fleming MR, Xiao L, Jackson KD. Vascular impact of cancer therapies: the case of BTK (Bruton tyrosine kinase) inhibitors. Circ Res. 2021; 128(12):1973-1987.","DOI":"10.1161\/CIRCRESAHA.121.318259"},{"key":"63653","doi-asserted-by":"crossref","unstructured":"McMullen JR, Boey EJ, Ooi JY. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014; 124(25):3829-3830.","DOI":"10.1182\/blood-2014-10-604272"},{"key":"63654","doi-asserted-by":"crossref","unstructured":"Barr PM, Brown JR, Hillmen P. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL. Blood. 2017; 129(19):2612-2615.","DOI":"10.1182\/blood-2016-12-737346"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283846\/76722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283846\/77205","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11480\/76722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:53Z","timestamp":1794045953000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":15,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283846","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}